



CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA
PHONE: +91-124-4135000 FAX: +91-124-4106490
E-mail: secretarial@ranbaxy.com

February 2, 2015

TO : STOCK EXCHANGES

Dear Sirs,

Enclosed please find Press Release dated February 2, 2015 titled **“Sun Pharma receives US FTC clearance for Ranbaxy acquisition”** which is being issued by the Company today.

This is for your information please.

Thanking you,

Yours faithfully,
for RANBAXY LABORATORIES LTD.

(SUSHIL K . PATAWARI)
COMPANY SECRETARY

Encl. : As above.

FOR IMMEDIATE RELEASE

Sun Pharma receives US FTC clearance for Ranbaxy acquisition

Mumbai and Gurgaon, India: February 02, 2015 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and Ranbaxy Laboratories Ltd (Reuters: RANB.BO, Bloomberg: RBXY IN, NSE: RANBAXY, BSE: 500359) today announced that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Ranbaxy by Sun Pharma and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).

The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition.

Sun Pharma and Ranbaxy also announced that the FTC accepted a proposed consent agreement pursuant to which, Sun Pharma and Ranbaxy have agreed to divest Ranbaxy's interests in generic minocycline tablets and capsules to an external third party.

Sun Pharma and Ranbaxy are working closely towards completion of the transaction and will comply with the conditions laid down in the FTC consent agreement within the specified time.

About Sun Pharma (CIN - L24230GJ1993PLC019050)

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 75% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2014, overall revenues were at US\$2.7 billion, of which US contributed US\$1.6 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

About Ranbaxy (CIN – L24231PB1961PLC003747)

Ranbaxy Limited is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed and emerging markets, many of which incorporate proprietary Novel Drug Delivery Systems and technologies developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. For more information, please visit www.ranbaxy.com.

For More Information Contact:

Sun Pharma

Nimish Desai

Tel Direct +91 22 6645 5717

Mobile +91 98203 30182

E mail nimish.desai@sunpharma.com

Frederick Castro

Tel Direct

+91 22 6645 5964

Mobile

+91 99206 65176

E mail

frederick.castro@sunpharma.com**Ranbaxy**

Koji Ogawa – Head Corporate Services

Tel +91 124 4135620

Email koji.ogawa@ranbaxy.com

Krishnan Ramalingam - General Manager – Global Corporate Communications

Tel

+91 9810042540

Email

krishnan.ramalingam@ranbaxy.com